{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:20:19Z","timestamp":1793701219789,"version":"4.5.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease. The increasing recognition and targeting of genetically defined DLBCLs highlight the need for robust classification algorithms. We previously characterized recurrent genetic alterations in DLBCL and identified 5 discrete subtypes, clusters 1 to 5 (C1-C5), with unique mechanisms of transformation, immune evasion, candidate treatment targets, and different outcomes after standard first-line therapy. Herein, we validate the C1 to C5 DLBCL taxonomy in an independent data set and use the expanded series of 699 primary DLBCLs to develop a probabilistic molecular classifier and confirm its performance in an independent test set. Using our previously assigned cluster labels as a reference, we systematically compared multiple machine learning models and strategies for input feature dimensionality reduction with a newly developed performance metric that captured the relationship between accuracy and confidence of class assignments. The winning neural network model, DLBclass, assigned all cases in the training\/validation and independent test sets with 91% and 89% accuracies, respectively. In the 75% of cases with confidence &amp;gt;0.7, DLBclass assignments were accurate in 97% of the training\/validation set and 98% of the test set. DLBclass enables robust prospective classification of single cases for inclusion in genetically guided clinical trials or practice and represents a framework for the development of genomics-based classification methods in other cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025652","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T16:28:43Z","timestamp":1734366523000},"page":"2041-2055","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["DLB\n                    <i>class<\/i>\n                    : a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6485-8773","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Chapuy","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"4German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-7621","authenticated-orcid":false,"given":"Timothy","family":"Wood","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-9552","authenticated-orcid":false,"given":"Chip","family":"Stewart","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6152-3169","authenticated-orcid":false,"given":"Andrew","family":"Dunford","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-4420","authenticated-orcid":false,"given":"Kirsty","family":"Wienand","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-3080","authenticated-orcid":false,"given":"Sumbul Jawed","family":"Khan","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3668-507X","authenticated-orcid":false,"given":"Nazli","family":"Serin","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1426-4594","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-1322","authenticated-orcid":false,"given":"Eleonora","family":"Calabretta","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-1654","authenticated-orcid":false,"given":"Joji","family":"Shimono","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4235-5813","authenticated-orcid":false,"given":"Samantha","family":"Van Seters","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6170-0043","authenticated-orcid":false,"given":"Sam","family":"Wisemann","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-8996","authenticated-orcid":false,"given":"Saveliy","family":"Belkin","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-4259","authenticated-orcid":false,"given":"David","family":"Heimann","sequence":"additional","affiliation":[{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-6897","authenticated-orcid":false,"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"5Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"7Krantz Family Center for Cancer Research and Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2025050111221949700_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6769","key":"2025050111221949700_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"2025050111221949700_bib3","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025050111221949700_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025050111221949700_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2025050111221949700_bib6","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2025050111221949700_bib7","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025050111221949700_bib8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2025050111221949700_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2025050111221949700_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK inhibition modulates distinct PI3K\/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"issue":"22","key":"2025050111221949700_bib11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal\u00a0gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025050111221949700_bib12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"7277","key":"2025050111221949700_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"7332","key":"2025050111221949700_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"5","key":"2025050111221949700_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2025050111221949700_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2025050111221949700_bib17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025050111221949700_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"20","key":"2025050111221949700_bib19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"15","key":"2025050111221949700_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025050111221949700_bib21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"2025050111221949700_bib22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ccell.2021.10.007","article-title":"PHOENIX rises: genomic-based therapies for diffuse large B cell lymphoma","volume":"39","author":"Mondello","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"2025050111221949700_bib23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2025050111221949700_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17132","article-title":"Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL)","volume":"192","author":"Runge","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025050111221949700_bib25","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study [abstract]","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025050111221949700_bib26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol"},{"issue":"85","key":"2025050111221949700_bib27","first-page":"2825","article-title":"Scikit-learn: machine learning in python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J\u00a0Mach Learn Res"},{"issue":"7","key":"2025050111221949700_bib28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2025050111221949700_bib29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/leu.2015.328","article-title":"Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma","volume":"30","author":"Hartmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2025050111221949700_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3324\/haematol.2018.203224","article-title":"JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell\/histiocyte-rich large B-cell lymphoma","volume":"104","author":"Schuhmacher","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"2025050111221949700_bib31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood.2020010432","article-title":"SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence","volume":"138","author":"Gao","year":"2021","journal-title":"Blood"},{"issue":"7841","key":"2025050111221949700_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","article-title":"Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture","volume":"589","author":"Yusufova","year":"2021","journal-title":"Nature"},{"issue":"1","key":"2025050111221949700_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"issue":"12","key":"2025050111221949700_bib34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"2025050111221949700_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","article-title":"TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate","volume":"182","author":"Venturutti","year":"2020","journal-title":"Cell"},{"issue":"14","key":"2025050111221949700_bib36","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood.2023019865","article-title":"MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8","volume":"142","author":"Mandato","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025050111221949700_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/2643-3230.BCD-22-0007","article-title":"Distinct genetically determined origins of Myd88\/BCL2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies","volume":"4","author":"Flumann","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025050111221949700_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2025050111221949700_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","article-title":"Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas","volume":"54","author":"Dersh","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"2025050111221949700_bib40","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1038\/s41467-023-42585-9","article-title":"Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing","volume":"14","author":"Ptashkin","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"2025050111221949700_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"19","key":"2025050111221949700_bib42","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","article-title":"The race is on: bispecifics vs CAR T cells in B-cell lymphoma","volume":"7","author":"Gurumurthi","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025050111221949700_bib43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/hematology.2023000438","article-title":"Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas","volume":"2023","author":"Major","year":"2023","journal-title":"Hematology"},{"issue":"16","key":"2025050111221949700_bib44","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023009813","article-title":"Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging","volume":"7","author":"Wright","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025050111221949700_bib45","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/18\/2041\/2372325\/blood_bld-2024-025652-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/18\/2041\/2372325\/blood_bld-2024-025652-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:22:41Z","timestamp":1746098561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/18\/2041\/534607\/DLBclass-a-probabilistic-molecular-classifier-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":45,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025652","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}